

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|              |        |  |
|--------------|--------|--|
| NEWS 1       |        | Web Page URLs for STN Seminar Schedule - N. America  |
| NEWS 2       |        | "Ask CAS" for self-help around the clock   |
| NEWS 3       | AUG 09 | INSPEC enhanced with 1898-1968 archive   |
| NEWS 4       | AUG 28 | ADISCTI Reloaded and Enhanced  |
| NEWS 5       | AUG 30 | CA(SM)/CPlus(SM) Austrian patent law changes   |
| NEWS 6       | SEP 11 | CA/CPlus enhanced with more pre-1907 records   |
| NEWS 7       | SEP 21 | CA/CPlus fields enhanced with simultaneous left and right truncation   |
| NEWS 8       | SEP 25 | CA(SM)/CPlus(SM) display of CA Lexicon enhanced  |
| NEWS 9       | SEP 25 | CAS REGISTRY(SM) no longer includes Concord 3D coordinates   |
| NEWS 10      | SEP 25 | CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine   |
| NEWS 11      | SEP 28 | CEABA-VTB classification code fields reloaded with new classification scheme   |
| NEWS 12      | OCT 19 | LOGOFF HOLD duration extended to 120 minutes   |
| NEWS 13      | OCT 19 | E-mail format enhanced   |
| NEWS 14      | OCT 23 | Option to turn off MARPAT highlighting enhancements available  |
| NEWS 15      | OCT 23 | CAS Registry Number crossover limit increased to 300,000 in multiple databases   |
| NEWS 16      | OCT 23 | The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded   |
| NEWS 17      | OCT 30 | CHEMLIST enhanced with new search and display field  |
| NEWS 18      | NOV 03 | JAPIO enhanced with IPC 8 features and functionality   |
| NEWS 19      | NOV 10 | CA/CPlus F-Term thesaurus enhanced   |
| NEWS 20      | NOV 10 | STN Express with Discover! free maintenance release Version 8.01c now available  |
| NEWS 21      | NOV 13 | CA/CPlus pre-1967 chemical substance index entries enhanced with preparation role  |
| NEWS 22      | NOV 20 | CAS Registry Number crossover limit increased to 300,000 in additional databases   |
| NEWS 23      | NOV 20 | CA/CPlus to MARPAT accession number crossover limit increased to 50,000  |
| NEWS 24      | NOV 20 | CA/CPlus patent kind codes will be updated   |
| NEWS 25      | DEC 01 | CAS REGISTRY updated with new ambiguity codes  |
| NEWS EXPRESS |        | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. |
| NEWS HOURS   |        | STN Operating Hours Plus Help Desk Availability  |
| NEWS LOGIN   |        | Welcome Banner and News Items  |
| NEWS IPC8    |        | For general information regarding STN implementation of IPC 8  |
| NEWS X25     |        | X.25 communication option no longer available  |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:38:45 ON 06 DEC 2006

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 0.21             | 0.21          |

FILE 'REGISTRY' ENTERED AT 09:39:01 ON 06 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

DICTIONARY FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSQA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10824037.str



```

chain nodes :
15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
1-15 4-9
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :
1-2 1-6 1-15 2-3 3-4 4-5 5-6
exact bonds :
3-8 4-9 5-7 7-8
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

```

G1:C,H

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS  
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:39:30 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 13 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 720 TO 1640  
PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:39:34 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1318 TO ITERATE

100.0% PROCESSED 1318 ITERATIONS 204 ANSWERS  
SEARCH TIME: 00.00.01

L3 204 SEA SSS FUL L1

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 166.94           | 167.15        |

FILE 'CAPLUS' ENTERED AT 09:39:38 ON 06 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Dec 2006 VOL 145 ISS 24  
FILE LAST UPDATED: 5 Dec 2006 (20061205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s l3 full  
L4 12 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:1176029 CAPLUS  
TITLE: Preparation of benzotriazinones and phenoxazines as  $\alpha$ 1 adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia  
INVENTOR(S): Sarma, Pakala Kumara Savithru; Sharma, Somesh; Dharmarajan, Sankaranarayanan; Shelke, Sandeep Y.; Pal, Arani; Kondaskar, Atul; Gupta, Praful; Chugh, Anita; Tiwari, Atul; Nanda, Kamna  
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
SOURCE: PCT Int. Appl., 83pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2006117760   | A1   | 20061109 | WO 2006-IB51392 | 20060503   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  |      |          |                 |            |
| PRIORITY APPLN. INFO.:  |      |          | IN 2005-DE1099  | A 20050503 |
| GI  |      |          |                 |            |



II

AB Compds. R1-A-X1R2R3 [I, wherein X1 = N or CR4; R4 = H, OH or alkyl; A = aryl, aryloxy, alkyl, etc.; R1 - R3 = H, halo, alkyl, etc.; R2 and R3 together with X1 to which they are attached also form a ring] and pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides or metabolites thereof were prepared as  $\alpha$ 1 adrenergic receptor antagonists. A number of benzotriazinones and phenoxazines were disclosed as examples. For instance, N-alkylation of 1,2,3-benzotriazin-4(3H)-one with 1,3-dibromopropane followed by amination of the resulting bromide with 4-(2-methoxyphenyl)piperidin-4-ol gave II, which was converted into its salt by treatment with HCl. The invented compds. showed inhibition against  $\alpha$ 1a and  $\alpha$ 1b adrenergic receptors with Ki values of 0.5-2500 nM and 5-1333 nM, resp. Therefore, I can be used to treat diseases mediated through  $\alpha$ 1a and/or  $\alpha$ 1b adrenergic receptors such as benign prostatic hyperplasia (BPH) and related symptoms thereof.


IT 914290-23-6P 914290-45-2P 914290-82-7P  
914291-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzotriazinones and phenoxazines as  $\alpha$ 1 adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia)

RN 914290-23-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● x HCl


RN 914290-45-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




● x HCl


RN 914290-82-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 914291-00-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



IT 914289-94-4P 914289-95-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of benzotriazinones and phenoxazines as  $\alpha 1$  adrenergic  
receptor antagonists for the treatment of benign prostatic hyperplasia)  
RN 914289-94-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



RN 914289-95-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:162035 CAPLUS

DOCUMENT NUMBER: 142:233377

TITLE: Pharmaceutical composition and method using a  
combination of an opioid receptor antagonist and an  
 $\alpha 2\delta$  ligand for the prevention and  
treatment of addiction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy,  
Stanton Furst; McLean, Stafford

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| US 2005043345          | A1   | 20050224 | US 2004-870821  | 20040617   |
| CA 2535814             | AA   | 20050303 | CA 2004-2535814 | 20040809   |
| WO 2005018670          | A1   | 20050303 | WO 2004-IB2602  | 20040809   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| EP 1658098             | A1   | 20060524 | EP 2004-744237  | 20040809   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK   |          |                 |            |
| BR 2004013608          | A  | 20061017 | BR 2004-13608   | 20040809   |
| PRIORITY APPLN. INFO.: |  |          | US 2003-497372P | P 20030822 |
|                        |  |          | WO 2004-IB2602  | W 20040809 |

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and an  $\alpha 2\delta$  ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IT 778582-19-7 778582-23-3 778582-27-7




778582-32-4 778582-34-6 778582-60-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(opioid receptor antagonist- $\alpha$ 2 $\delta$  ligand combination for  
prevention and treatment of addiction)


RN 778582-19-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-  
azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-23-3 CAPLUS

CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-  
azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-27-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-  
methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-32-4 CAPLUS


CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-  
methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX  
NAME)



RN 778582-34-6 CAPLUS


CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS

CN Benzamide, 3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:160837 CAPLUS

DOCUMENT NUMBER: 142:233372

TITLE: Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND   | DATE     | APPLICATION NO. | DATE     |
|---------------|--|----------|-----------------|----------|
| US 2005043327 | A1   | 20050224 | US 2004-870209  | 20040617 |
| CA 2536280    | AA   | 20050303 | CA 2004-2536280 | 20040809 |
| WO 2005018645 | A1   | 20050303 | WO 2004-IB2596  | 20040809 |
| W:            | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |          |
| RW:           | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |          |
| EP 1658082    | A1   | 20060524 | EP 2004-744231  | 20040809 |
| R:            | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK   |          |                 |          |

BR 2004013693  
PRIORITY APPLN. INFO.:

A 20061024

BR 2004-13693  
US 2003-496803P  
WO 2004-IB2596

20040809  
P 20030821  
W 20040809

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.


IT 778582-19-7 778582-23-3 778582-27-7  
778582-32-4 778582-34-6 778582-60-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)


RN 778582-19-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-23-3 CAPLUS

CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-27-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-32-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-34-6 CAPLUS

CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS

CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:995777 CAPLUS

DOCUMENT NUMBER: 141:406121

TITLE: New pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms  
INVENTOR(S): Saltarelli, Mario David; Lowe, John Adams

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 59 pp., Division of U.S. Ser. No. 572,619.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND              | DATE     | APPLICATION NO. | DATE        |
|------------------------|-------------------|----------|-----------------|-------------|
| US 2004229911          | A1                | 20041118 | US 2004-867123  | 20040614    |
| PRIORITY APPLN. INFO.: |                   |          | US 2000-572619  | A3 20000517 |
| OTHER SOURCE(S):       | MARPAT 141:406121 |          |                 |             |

AB The present invention relates to new pharmaceutical uses for compds. that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically,

it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI (selective serotonin reuptake inhibitor) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.


IT 208837-35-8 310433-73-9 310433-74-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new pharmaceutical combinations of nitric oxide synthase inhibitors and NK-1 receptor antagonists and selective serotonin reuptake inhibitors for treatment of disorders facilitated by altering circadian rhythms)


RN 208837-35-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 310433-73-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 310433-74-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN



ACCESSION NUMBER: 2004:872783 CAPLUS

DOCUMENT NUMBER: 141:366141

TITLE: Preparation of 3-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as opioid

receptor modulators  
 INVENTOR(S): Coe, Jotham Wadsworth; Mchardy, Stanton Furst;  
 Bashore, Crystal Gayle  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE              | APPLICATION NO. | DATE       |
|---|------|-------------------|-----------------|------------|
| WO 2004089908   | A2   | 20041021          | WO 2004-IB1189  | 20040402   |
| WO 2004089908   | A3   | 20041223          |                 |            |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br>RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |                   |                 |            |
| CA 2522323  | AA   | 20041021          | CA 2004-2522323 | 20040402   |
| EP 1615894  | A2   | 20060118          | EP 2004-725450  | 20040402   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR   |      |                   |                 |            |
| BR 2004009307   | A    | 20060425          | BR 2004-9307    | 20040402   |
| JP 2006522795   | T2   | 20061005          | JP 2006-506489  | 20040402   |
| NL 1025932  | A1   | 20041018          | NL 2004-1025932 | 20040413   |
| NL 1025932  | C2   | 20051122          |                 |            |
| US 2004259859   | A1   | 20041223          | US 2004-824037  | 20040414   |
| PRIORITY APPLN. INFO.:  |      |                   | US 2003-462629P | P 20030414 |
|   |      |                   | WO 2004-IB1189  | W 20040402 |
| OTHER SOURCE(S):  |      | MARPAT 141:366141 |                 |            |
| GI  |      |                   |                 |            |



AB 3-Azabicyclo[3.2.1]octanes, such as I [R = H, OH, CN, NH<sub>2</sub>, CONH<sub>2</sub>, alkyl, alkynyl, alkylsulfonylamino, etc.; R<sub>3</sub> = alkyl, arylalkyl, heteroarylalkyl, etc.; R<sub>8</sub> = H, OH, OMe] and specifically II, were prepared for therapeutic use in the treatment of disease states, disorders and conditions mediated by opioid receptors, such as irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders.

IT 778582-18-6P 778582-19-7P 778582-20-0P  
 778582-21-1P 778582-22-2P 778582-23-3P  
 778582-24-4P 778582-25-5P 778582-26-6P


778582-27-7P 778582-28-8P 778582-29-9P  
 778582-30-2P 778582-31-3P 778582-32-4P  
 778582-33-5P 778582-34-6P 778582-35-7P  
 778582-36-8P 778582-37-9P 778582-38-0P  
 778582-39-1P 778582-40-4P 778582-41-5P  
 778582-42-6P 778582-43-7P 778582-44-8P  
 778582-45-9P 778582-46-0P 778582-47-1P  
 778582-48-2P 778582-49-3P 778582-50-6P  
 778582-51-7P 778582-52-8P 778582-53-9P  
 778582-54-0P 778582-55-1P 778582-56-2P  
 778582-57-3P 778582-58-4P 778582-59-5P  
 778582-60-8P 778582-61-9P 778582-62-0P  
 778582-63-1P 778582-64-2P 778582-65-3P  
 778582-66-4P 778582-67-5P 778582-68-6P  
 778582-69-7P 778582-70-0P 778582-71-1P  
 778582-72-2P 778582-73-3P 778582-74-4P  
 778582-75-5P 778582-76-6P 778582-77-7P  
 778582-78-8P 778582-79-9P 778582-80-2P  
 778582-81-3P 778582-82-4P 778582-83-5P  
 778582-84-6P 778582-85-7P 778582-86-8P  
 778582-87-9P 778582-88-0P 778582-89-1P  
 778582-90-4P 778582-91-5P 778582-92-6P  
 778582-93-7P 778582-94-8P 778582-95-9P  
 778582-96-0P 778582-97-1P 778582-98-2P  
 778582-99-3P 778583-01-0P 778583-05-4P  
 778583-07-6P 778583-09-8P 778583-11-2P  
 778583-12-3P 778583-14-5P 778583-17-8P  
 778583-18-9P 778583-19-0P 778583-20-3P  
 778583-21-4P 778583-22-5P 778583-23-6P  
 778583-24-7P 778583-25-8P 778583-26-9P  
 778583-27-0P 778583-28-1P 778583-29-2P  
 778583-30-5P 778583-31-6P 778583-32-7P  
 778583-33-8P 778583-34-9P 778583-35-0P  
 778583-36-1P 778583-37-2P 778583-38-3P  
 778583-39-4P 778583-40-7P 778583-41-8P  
 778583-42-9P 778583-43-0P 778583-44-1P  
 778583-45-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical  
 compns. as opioid receptor modulators)


RN 778582-18-6 CAPLUS

CN Phenol, 3-[3-(cyclopropylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA  
 INDEX NAME)




RN 778582-19-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-  
 azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-20-0 CAPLUS

CN Phenol, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-21-1 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-22-2 CAPLUS

CN Methanesulfonamide, N-[3-[8-hydroxy-3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-23-3 CAPLUS


CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)






RN 778582-24-4 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-[3-(1-hydroxycyclohexyl)propyl]-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778582-25-5 CAPLUS

CN Benzamide, 3-[3-(cyclopropylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-26-6 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-2-[[8-(3-hydroxyphenyl)-3-azabicyclo[3.2.1]oct-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 778582-27-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-28-8 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-29-9 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-2-[[8-(3-hydroxyphenyl)-8-methoxy-3-azabicyclo[3.2.1]oct-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 778582-30-2 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-31-3 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-32-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-33-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778582-34-6 CAPLUS

CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-35-7 CAPLUS

CN Ethanone, 1-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 778582-36-8 CAPLUS


CN Benzamide, 3-(3-ethyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-37-9 CAPLUS  
 CN Benzamide, 3-[8-methoxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]-  
 (9CI) (CA INDEX NAME)




RN 778582-38-0 CAPLUS  
 CN Benzamide, 3-(8-methoxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA  
 INDEX NAME)



RN 778582-39-1 CAPLUS  
 CN Benzamide, 3-[8-methoxy-3-(1H-pyrrol-2-ylmethyl)-3-azabicyclo[3.2.1]oct-8-  
 yl]- (9CI) (CA INDEX NAME)




RN 778582-40-4 CAPLUS  
 CN Benzamide, 3-(3-hexyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA  
 INDEX NAME)




RN 778582-41-5 CAPLUS

CN Benzamide, 3-[3-(2-ethylbutyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]-(9CI) (CA INDEX NAME)




RN 778582-42-6 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(1-methyl-1H-pyrrol-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]-(9CI) (CA INDEX NAME)




RN 778582-43-7 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-thienylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-(9CI) (CA INDEX NAME)




RN 778582-44-8 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(2-thiazolylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-(9CI) (CA INDEX NAME)




RN 778582-45-9 CAPLUS

CN Benzamide, 3-[8-methoxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-46-0 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-phenyl-2-propynyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-47-1 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-phenylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-48-2 CAPLUS

CN Benzamide, 3-[3-(1H-indol-3-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-49-3 CAPLUS

CN Benzamide, 3-[3-(2-benzofuranylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-50-6 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-51-7 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-52-8 CAPLUS

CN Benzamide, 3-[3-[(4-chloro-2-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-53-9 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-54-0 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[2-(2-phenylethoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-55-1 CAPLUS


CN Ethanesulfonamide, N-[3-(8-hydroxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-56-2 CAPLUS


CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)






RN 778582-57-3 CAPLUS

CN Benzamide, 3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-58-4 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-59-5 CAPLUS


CN Benzamide, 3-[8-methoxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS


CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-61-9 CAPLUS

CN Ethanesulfonamide, N-[3-(3-hexyl-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-62-0 CAPLUS

CN Benzamide, 3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-63-1 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-pyridinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-64-2 CAPLUS


CN Benzamide, 3-[8-methoxy-3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-65-3 CAPLUS  
 CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-thienylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-66-4 CAPLUS  
 CN Ethanesulfonamide, N-[3-[3-(cyclohexylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-67-5 CAPLUS  
 CN Benzamide, 3-[3-(9H-fluoren-2-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-68-6 CAPLUS  
 CN Benzamide, 3-[8-methoxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-69-7 CAPLUS

CN Benzamide, 3-[[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-70-0 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-71-1 CAPLUS

CN Ethanesulfonamide, N-[3-(8-hydroxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-72-2 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-phenyl-2-propynyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-73-3 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-phenylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-74-4 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[(4-chlorophenyl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-75-5 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(1H-indol-3-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-76-6 CAPLUS

CN Ethanesulfonamide, N-[3-[3-(2-benzofuranylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-77-7 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-78-8 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(1-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-79-9 CAPLUS


CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(4-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-80-2 CAPLUS


CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)

azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-81-3 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-82-4 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[2-(2-phenylethoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-83-5 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(4-hydroxy-1-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-84-6 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-85-7 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-86-8 CAPLUS

CN Ethanesulfonamide, N-[3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-87-9 CAPLUS


CN Ethanesulfonamide, N-[3-[3-(9H-fluoren-2-ylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-88-0 CAPLUS


CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)






RN 778582-89-1 CAPLUS

CN Ethanesulfonamide, N-[3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-90-4 CAPLUS

CN Methanesulfonamide, N-[3-[3-(cyclopropylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-91-5 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-92-6 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-methylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-93-7 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-94-8 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-95-9 CAPLUS

CN Methanesulfonamide, N-[3-[3-(2-ethylbutyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-96-0 CAPLUS


CN Methanesulfonamide, N-[3-(3-hexyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 778582-97-1 CAPLUS


CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-pyridinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)

azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-98-2 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-thiazolylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-99-3 CAPLUS

CN Methanesulfonamide, N-[3-(3-heptyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778583-01-0 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-05-4 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-07-6 CAPLUS

CN Methanesulfonamide, N-[3-[3-(2-ethylhexyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-09-8 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778583-11-2 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-12-3 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-chlorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-14-5 CAPLUS

CN Methanesulfonamide, N-[3-[3-(1H-indol-3-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-17-8 CAPLUS

CN Methanesulfonamide, N-[3-[3-(2-benzofuranylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-18-9 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(1-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-19-0 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-20-3 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(4-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-21-4 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-22-5 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-chloro-2-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-23-6 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-24-7 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-25-8 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-26-9 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-27-0 CAPLUS

CN Methanesulfonamide, N-[3-[3-([1,1'-biphenyl]-4-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-28-1 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-29-2 CAPLUS

CN Methanesulfonamide, N-[3-[3-(9H-fluoren-2-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-30-5 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-31-6 CAPLUS


CN Methanesulfonamide, N-[3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-32-7 CAPLUS


CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-(3-cyclohexylpropyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)






RN 778583-33-8 CAPLUS

CN Phenol, 3-[3-(3-cyclohexylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-34-9 CAPLUS

CN Benzamide, 3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-35-0 CAPLUS

CN Benzamide, 3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-36-1 CAPLUS

CN Benzamide, 3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778583-37-2 CAPLUS

CN Methanesulfonamide, N-[3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-38-3 CAPLUS

CN Methanesulfonamide, N-[3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-39-4 CAPLUS

CN Methanesulfonamide, N-[3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-40-7 CAPLUS

CN Acetamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 778583-41-8 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-[3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778583-42-9 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI)  
(CA INDEX NAME)




RN 778583-43-0 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI)  
(CA INDEX NAME)




RN 778583-44-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-(cyclopropylmethyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 778583-45-2 CAPLUS

CN Phenol, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




IT 778581-99-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical compns. as opioid receptor modulators)

RN 778581-99-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-aminophenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT 778581-81-0P 778581-83-2P 778581-84-3P

778581-85-4P 778581-86-5P 778581-87-6P

778581-88-7P 778581-89-8P 778581-90-1P

778581-91-2P 778581-92-3P 778581-93-4P

778581-94-5P 778581-95-6P 778581-96-7P

778581-97-8P 778581-98-9P 778582-00-6P

778582-01-7P 778582-02-8P 778582-03-9P

778582-04-0P 778582-05-1P 778582-06-2P

778582-07-3P 778582-08-4P 778582-09-5P

778582-10-8P 778582-11-9P 778582-12-0P

778582-13-1P 778582-14-2P 778582-15-3P


778582-16-4P 778582-17-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical compns. as opioid receptor modulators)


RN 778581-81-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 778581-83-2 CAPLUS


CN 3-Azabicyclo[3.2.1]octane, 8-chloro-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 778581-84-3 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane, 8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]-  
 (9CI) (CA INDEX NAME)




RN 778581-85-4 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane, 8-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 778581-86-5 CAPLUS  
 CN Phenol, 3-(3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



RN 778581-87-6 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-(3-hydroxyphenyl)-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 778581-88-7 CAPLUS  
 CN Phenol, 3-(3-azabicyclo[3.2.1]oct-8-yl)-, hydrochloride (9CI) (CA INDEX  
 NAME)




● HCl


RN 778581-89-8 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-[3-  
 [(trifluoromethyl)sulfonyl]oxy]phenyl]-, phenylmethyl ester (9CI) (CA  
 INDEX NAME)




RN 778581-90-1 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-(3-aminophenyl)-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 778581-91-2 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-[3-  
 [(methylsulfonyl)amino]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 778581-92-3 CAPLUS  
 CN Methanesulfonamide, N-[3-(3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA  
 INDEX NAME)




RN 778581-93-4 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-bromophenyl)-3-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)




RN 778581-94-5 CAPLUS  
 CN Boronic acid, [3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778581-95-6 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-hydroxyphenyl)-3-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)



RN 778581-96-7 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 778581-97-8 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-aminophenyl)-3-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)




RN 778581-98-9 CAPLUS

CN Methanesulfonamide, N-[3-[8-hydroxy-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-00-6 CAPLUS

CN Methanesulfonamide, N-[3-(8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-01-7 CAPLUS

CN Benzonitrile, 3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-02-8 CAPLUS

CN Benzamide, 3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)







RN 778582-03-9 CAPLUS  
 CN Benamide, 3-(8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-04-0 CAPLUS  
 CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 778582-05-1 CAPLUS  
 CN Ethanesulfonamide, N-[3-(8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-06-2 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane, 8-(3-bromophenyl)-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 778582-07-3 CAPLUS  
 CN Boronic acid, [3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-08-4 CAPLUS

CN Phenol, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI)  
(CA INDEX NAME)




RN 778582-09-5 CAPLUS

CN Phenol, 3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)




RN 778582-10-8 CAPLUS

CN Benzenamine, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-  
(9CI) (CA INDEX NAME)




RN 778582-11-9 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-12-0 CAPLUS

CN Methanesulfonamide, N-[3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 778582-13-1 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 778582-14-2 CAPLUS

CN Ethanesulfonamide, 2-methoxy-N-[3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 778582-15-3 CAPLUS

CN Benzonitrile, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)




RN 778582-16-4 CAPLUS

CN Benzamide, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-17-5 CAPLUS

CN Benzamide, 3-(8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:207617 CAPLUS

DOCUMENT NUMBER: 138:369039

TITLE: Synthesis and pharmacology of site specific cocaine abuse treatment agents: 8-substituted isotropane (3-azabicyclo[3.2.1]octane) dopamine uptake inhibitors  
 AUTHOR(S): Kim, Deog-Il; Schweri, Margaret M.; Deutsch, Howard M.  
 CORPORATE SOURCE: Georgia Institute of Technology, School of Chemistry and Biochemistry, Atlanta, GA, 30332-0400, USA  
 SOURCE: Journal of Medicinal Chemistry (2003), 46(8), 1456-1464

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 138:369039

GI



- AB A series of 8-substituted-3-azabicyclo[3.2.1]octanes (isotropanes) were synthesized and tested for inhibitor potency using [ $^3\text{H}$ ]WIN 35,428 binding at the dopamine (DA) transporter, [ $^3\text{H}$ ]citalopram binding at the serotonin (5-HT) transporter, and [ $^3\text{H}$ ]DA uptake assays. The synthesis started with a Mannich condensation of cyclopentanone, benzylamine, and formaldehyde to afford N-benzyl-3-azabicyclo[3.2.1]octan-8-one (I). The 8-Ph group was introduced by Grignard addition to ketone I or nucleophilic displacement via a triflate of the corresponding alc. The 8 $\beta$ -phenyl-8 $\alpha$ -alcs. from Grignard addition generally have low affinity for the two transporters and do not effectively inhibit the uptake of [ $^3\text{H}$ ]DA. The 8 $\beta$ -Ph compound (II) without the hydroxyl group at C-8 was much more potent (22-fold) for [ $^3\text{H}$ ]WIN 35,428 binding inhibition than the corresponding 8 $\beta$ -phenyl-8 $\alpha$ -hydroxy compound. The 8 $\alpha$ -Ph compound was almost as potent as cocaine in binding to the DA transporter ( $\text{IC}_{50} = 234 \text{ nM}$  vs  $159 \text{ nM}$  for cocaine); whereas the C-8 epimer was somewhat less potent ( $\text{IC}_{50} = 785 \text{ nM}$ ). The lower potency of II ( $\beta$ -orientation of 8-Ph group) as compared to II ( $\alpha$ -orientation) was unexpected, based on modeling studies comparing the new compds. to WIN 35,065-2, an analog of cocaine. The benzhydryl ethers at C-8 (III), analogous to the benztropines, had better selectivity than the corresponding Ph compds. for the DA transporter as compared to the 5-HT transporter. The isotropane and benzisotropine analogs seem to bind in a manner that is more similar to that of the benztropine compds. rather than those of cocaine and WIN 35,065-2.
- IT 521944-10-5P 521944-11-6P  
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 8-substituted isotropane (3-Azabicyclo[3.2.1]octane) cocaine analogs and evaluation of their activity as dopamine uptake inhibitors for the potential treatment of cocaine abuse)
- RN 521944-10-5 CAPLUS
- CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-3-(phenylmethyl)-, (8-syn)- (9CI)  
 (CA INDEX NAME)


Relative stereochemistry.



RN 521944-11-6 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 521944-12-7P 521944-14-9P 521944-19-4P  
521944-20-7P 521944-21-8P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 8-substituted isotropane (3-Azabicyclo[3.2.1]octane) cocaine analogs and evaluation of their activity as dopamine uptake inhibitors for the potential treatment of cocaine abuse)

RN 521944-12-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-14-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-19-4 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(4-chlorophenyl)-3-(phenylmethyl)-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-20-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-(phenylmethyl)-, (8-syn)-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-21-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-, (8-syn)- (9CI) (CA INDEX  
NAME)

Relative stereochemistry.



IT 15466-28-1P 521944-13-8P 521944-22-9P  
521944-23-0P 521944-24-1P 521944-25-2P  
521944-26-3P 521944-27-4P 521944-28-5P  
521944-29-6P 521944-30-9P 521944-31-0P  
521944-32-1P 522608-85-1P 522608-88-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)

(preparation of 8-substituted isotropane (3-Azabicyclo[3.2.1]octane) cocaine  
analogs and evaluation of their activity as dopamine uptake inhibitors  
for the potential treatment of cocaine abuse)

RN 15466-28-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl-, (8-syn)- (9CI) (CA  
INDEX NAME)


Relative stereochemistry.



RN 521944-13-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-22-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-methyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 521944-23-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-3-(phenylmethyl)-, hydrochloride, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-24-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(4-chlorophenyl)-3-(phenylmethyl)-, hydrochloride, (8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 521944-25-2 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, hydrochloride,  
 (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-26-3 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-(phenylmethyl)-,  
 hydrochloride, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 521944-27-4 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-, hydrochloride, (8-syn)- (9CI) (CA  
 INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-28-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-, hydrochloride, (8-syn)-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-29-6 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8-phenyl-, hydrochloride, (8-syn)-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-30-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-(4-chlorophenyl)-3-methyl-, hydrochloride,  
(8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-31-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-phenyl-, hydrochloride, (8-syn)- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 521944-32-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl-, hydrochloride, (8-syn)-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 522608-85-1 CAPLUS


CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, (8-anti)- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 522608-88-4 CAPLUS  
CN 3-Azabicyclo[3.2.1]octane, 8-phenyl-3-(phenylmethyl)-, hydrochloride,  
(8-anti)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2000:841966 CAPLUS  
DOCUMENT NUMBER: 134:13350  
TITLE: Nitric oxide synthase (NOS) inhibitor combinations  
with other agents for treatment of disorders treatable  
by altering circadian rhythm  
INVENTOR(S): Saltarelli, Mario David; Lowe, John Adams, III  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: PCT Int. Appl., 113 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2000071107   | A2   | 20001130 | WO 2000-IB295   | 20000316   |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW |      |          |                 |            |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| CA 2374668  | AA   | 20001130 | CA 2000-2374668 | 20000316   |
| EP 1178784  | A1   | 20020213 | EP 2000-907891  | 20000316   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO   |      |          |                 |            |
| BR 2000010820   | A    | 20020305 | BR 2000-10820   | 20000316   |
| TR 200103351  | T2   | 20020621 | TR 2001-3351    | 20000316   |
| EE 200100611  | A    | 20030217 | EE 2001-611     | 20000316   |
| JP 2003523941   | T2   | 20030812 | JP 2000-619414  | 20000316   |
| HU 200301287  | A2   | 20030828 | HU 2003-1287    | 20000316   |
| CN 1617743  | A    | 20050518 | CN 2000-807878  | 20000316   |
| NO 2001005651   | A    | 20020118 | NO 2001-5651    | 20011120   |
| HR 2001000862   | A1   | 20030630 | HR 2001-862     | 20011120   |
| ZA 2001009555   | A    | 20040407 | ZA 2001-9555    | 20011120   |
| BG 106208   | A    | 20020930 | BG 2001-106208  | 20011211   |
| PRIORITY APPLN. INFO.:  |      |          | US 1999-135520P | P 19990521 |

AB New pharmaceutical uses are provided for compds. that exhibit activity as NOS inhibitors. Specifically, the invention provides the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either a selective serotonin reuptake inhibitor (SSRI) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.


IT 208837-35-8 310433-73-9 310433-74-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide synthase inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm)


RN 208837-35-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 310433-73-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 310433-74-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-furanylmethyl)- (9CI) (CA INDEX NAME)




TITLE: Preparation of 6-phenylpyridyl-2-amines as NOS inhibitors  
 INVENTOR(S): Lowe, John Adams III  
 PATENT ASSIGNEE(S): Pfizer Inc., USA; Lowe, John Adams III  
 SOURCE: PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE        |
|---|------|----------|------------------|-------------|
| WO 9824766  | A1   | 19980611 | WO 1997-IB1446   | 19971117    |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU |      |          |                  |             |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG  |      |          |                  |             |
| CA 2273479  | AA   | 19980611 | CA 1997-2273479  | 19971117    |
| CA 2273479  | C    | 20060207 |                  |             |
| AU 9747917  | A1   | 19980629 | AU 1997-47917    | 19971117    |
| EP 946512   | A1   | 19991006 | EP 1997-910587   | 19971117    |
| EP 946512   | B1   | 20031008 |                  |             |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO   |      |          |                  |             |
| CN 1239952  | A    | 19991229 | CN 1997-180350   | 19971117    |
| CN 1117077  | B    | 20030806 |                  |             |
| BR 9714381  | A    | 20000502 | BR 1997-14381    | 19971117    |
| JP 2000505814   | T2   | 20000516 | JP 1998-525397   | 19971117    |
| JP 3604399  | B2   | 20041222 |                  |             |
| NZ 335733   | A    | 20010126 | NZ 1997-335733   | 19971117    |
| HU 200001848  | A2   | 20010428 | HU 2000-1848     | 19971117    |
| AT 251612   | E    | 20031015 | AT 1997-910587   | 19971117    |
| PT 946512   | T    | 20040130 | PT 1997-910587   | 19971117    |
| ES 2206691  | T3   | 20040516 | ES 1997-910587   | 19971117    |
| CZ 293863   | B6   | 20040818 | CZ 1999-2017     | 19971117    |
| TW 491840   | B    | 20020621 | TW 1997-86117501 | 19971122    |
| ZA 9710906  | A    | 19990609 | ZA 1997-10906    | 19971204    |
| AP 848  | A    | 20000609 | AP 1997-1156     | 19971204    |
| W: BW, GM, KE, UG, ZM, ZW   |      |          |                  |             |
| US 6235750  | B1   | 20010522 | US 1999-325480   | 19990603    |
| NO 9902725  | A    | 19990604 | NO 1999-2725     | 19990604    |
| NO 313517   | B1   | 20021014 |                  |             |
| KR 2000057413   | A    | 20000915 | KR 1999-704981   | 19990604    |
| BG 103540   | A    | 20001229 | BG 1999-103540   | 19990630    |
| US 6333186  | B1   | 20011225 | US 2000-478479   | 20000106    |
| US 2002032191   | A1   | 20020314 | US 2001-802086   | 20010308    |
| AU 2001072050   | A5   | 20011115 | AU 2001-72050    | 20010913    |
| AU 766080   | B2   | 20031009 |                  |             |
| US 2002103227   | A1   | 20020801 | US 2001-965564   | 20010927    |
| US 2002106642   | A1   | 20020808 | US 2001-965594   | 20010927    |
| US 6800456  | B2   | 20041005 |                  |             |
| US 2004142924   | A1   | 20040722 | US 2003-678369   | 20031003    |
| JP 2005170924   | A2   | 20050630 | JP 2004-186311   | 20040624    |
| PRIORITY APPLN. INFO.:  |      |          | US 1996-32793P   | P 19961206  |
|   |      |          | AU 1997-47917    | A3 19971117 |
|   |      |          | JP 1998-525397   | A3 19971117 |
|   |      |          | WO 1997-IB1446   | W 19971117  |
|   |      |          | US 1999-325480   | A1 19990603 |
|   |      |          | US 2000-478479   | A3 20000106 |


OTHER SOURCE(S):

MARPAT 129:67702


GI




I



II



III



IV


AB The title compds. [I; G = II, III (n = 0, 1; Y = NR<sub>3</sub>R<sub>4</sub>, C1-6 alkyl, (un)substituted aralkyl; X = N when Y = (un)substituted C1-6 alkyl, aralkyl, and X = CH when Y = NR<sub>3</sub>R<sub>4</sub>; q = 0-2; m = 0-2; R<sub>3</sub>, R<sub>4</sub> = C1-6 alkyl, tetrahydronaphthalene and aralkyl; NR<sub>3</sub>R<sub>4</sub> = piperazino, pyrrolidino, etc.)] and their salts, which exhibit activity as nitric oxide synthase (NOS) inhibitors and as such useful in the treatment and prevention of central nervous system and other disorders, were prepared. Thus, e.g., the detailed 7-step synthesis of the title compound IV is described. Of 100 compds. I that were tested, all exhibited an IC<sub>50</sub> of < 10 μM for inhibition of either inducible or neuronal NOS.

IT 208837-31-4P 208837-33-6P 208837-35-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 6-phenylpyridyl-2-amines as NOS inhibitors)

RN 208837-31-4 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 208837-33-6 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(2-furanylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 208837-35-8 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 208837-80-3P 208837-81-4P 208837-82-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent).  
 (preparation of 6-phenylpyridyl-2-amines as NOS inhibitors)  
 RN 208837-80-3 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]phenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 208837-81-4 CAPLUS  
 CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)





RN 208837-82-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-[4-(6-amino-2-pyridinyl)phenyl]- (9CI)  
(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:178911 CAPLUS

DOCUMENT NUMBER: 112:178911

TITLE: Condensation of 4-phenyl-3,5-bis(ethoxycarbonyl)cyclopentane-1,2-dione with primary amines

AUTHOR(S): Afsah, E. M.; Osman, A. I.; Sofan, M.

CORPORATE SOURCE: Fac. Sci., Mansoura Univ., Mansoura, Egypt

SOURCE: Journal fuer Praktische Chemie (Leipzig) (1989),  
331(3), 461-5

CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 112:178911

GI

DOCUMENT TYPE:  
LANGUAGE:  
GI

CODEN: YHHPAL; ISSN: 0513-4870  
Journal  
Chinese




AB 3-Azabicyclo[3.3.1]nonanes, 3-azabicyclo[3.2.1]octanes, and 8-azabicyclo[3.2.1]octanes (.apprx.35 compds.) were prepared. Most of the compds. had strong analgesic activity; I was 2000 times as potent as morphine.

IT 83507-31-7P  
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent) (formation and reactions of)

RN 83507-31-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-methoxyphenyl)-3-(2-phenylethyl)-(9CI) (CA INDEX NAME)




IT 83507-59-9P 83507-60-2P 83507-61-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and analgesic activity of)


RN 83507-59-9 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-methoxy-8-(3-methoxyphenyl)-3-(2-phenylethyl)-, hydrochloride, syn- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl




II



III



IV



V


AB Condensation of the title compound I with primary aromatic amines gave the dianilides, which cyclized to cyclopentadiquinolines II (R = H, Me). Treatment of I with o-phenylenediamine, 2,3-diaminopyridine, or o-aminophenol gave cyclopentabisbenzodiazepine III (X = CH, X1 = NH) and -bispyridodiazepine III (X = N, X1 = NH) or -bisbenzoxazepine III (X = CH, X1 = O) resp. Pechmann reaction of I with m-cresol gave the bisbenzopyran IV. Mannich reaction of I with benzylamine afforded the 3-azabicyclo[3.2.1]octane V.

IT 126517-81-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 126517-81-5 CAPLUS

CN 3-Azabicyclo[3.2.1]octane-1,5-dicarboxylic acid, 6,7-dioxo-8-phenyl-3-(phenylmethyl)-, diethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1982:582185 CAPLUS

DOCUMENT NUMBER: 97:182185

TITLE: Synthesis and analgesic activity of azabicycloalkanes derivatives


AUTHOR(S): Zhou, Dehe; Fang, Sunan; Ge, Banglun; Li, Qingzhen; Li, Zhiyi; Dai, Qiyan; Wu, Ruiqin; Wu, Yizhi; Huang, Zhongming; Chen, Xinjian

CORPORATE SOURCE: Shanghai Inst. Mater. Med., Acad. Sin., Shanghai, Peop. Rep. China

SOURCE: Yaoxue Xuebao (1982), 17(7), 503-9

RN 83507-60-2 CAPLUS  
 CN Phenol, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]-, hydrochloride, syn- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 83507-61-3 CAPLUS  
 CN Benzenepropanoic acid, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl ester, hydrochloride, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1978:509115 CAPLUS  
 DOCUMENT NUMBER: 89:109115  
 TITLE: Bridged geminal diphenylpiperidines  
 INVENTOR(S): Eistetter, Klaus; Menge, Heinz Guenter  
 PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 44 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE     | APPLICATION NO. | DATE       |
|------------|------|----------|-----------------|------------|
| DE 2749584 | A1   | 19780518 | DE 1977-2749584 | 19771105   |
|            |      |          | LU 1976-76173   | A 19761111 |

PRIORITY APPLN. INFO.: For diagram(s), see printed CA Issue.

AB The bridged piperidine derivs. I (X = CH<sub>2</sub>, X<sub>1</sub> = CPh<sub>2</sub> optionally substituted by halogen or alkyl; X = (un)substituted CPh<sub>2</sub>, X<sub>1</sub> = CH<sub>2</sub>; X<sub>2</sub> = bond, NR<sub>1</sub>; R = R<sub>1</sub> = H, alkyl, aralkyl; m + n = 1-9] and their salts and N-oxides were prepared Thus, II (R<sub>2</sub> = OH) was stirred with C<sub>6</sub>H<sub>6</sub> and AlCl<sub>3</sub>


at 40° to give II (R2 = Ph). I are useful for treatment of disturbances of the central nervous system, e.g. Parkinson's disease (no data).

IT 67171-16-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(Friedel-Carfts reactions of, with benzene)

RN 67171-16-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl- (9CI) (CA INDEX NAME)




IT 67171-15-7P 67171-17-9P 67171-29-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 67171-15-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8,8-diphenyl- (9CI) (CA INDEX NAME)



RN 67171-17-9 CAPLUS


CN 3-Azabicyclo[3.2.1]octane, 3-methyl-8,8-diphenyl-, hydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 67171-29-3 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 8-chloro-3-methyl-8-phenyl-, hydrochloride  
(9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:64884 CAPLUS

DOCUMENT NUMBER: 66:64884

TITLE: Fragmentation reaction of azabicyclic compounds

AUTHOR(S): Oida, Sadao; Kurabayashi, Masaaki; Ohki, Eiji

CORPORATE SOURCE: Sankyo Co., Ltd., Tokyo, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1966), 14(12), 1418-24

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB A mixture of 1.45 g. 3-methyl-9 $\beta$ -hydroxy-9 $\alpha$ -phenyl-3-azabicyclo[3.3.1]nonane (I), 30 ml. dry EtOH, and 3 ml. concentrated H<sub>2</sub>SO<sub>4</sub> refluxed 4 hrs. gave 1.55 g. 3-methyl-9 $\beta$ -ethoxy-9 $\alpha$ -phenyl-3-azabicyclo[3.3.1]nonane (II), b<sub>3</sub> 150-60° (bath temperature), purified as the picrate, decomposed at 200°. The corresponding 9 $\alpha$ -hydroxy compound (III) also gave II on refluxing with alc. H<sub>2</sub>SO<sub>4</sub>. In each case a minor amount of another product, possibly the 9 $\alpha$ -ethoxy epimer, was obtained. Refluxing III with methanolic H<sub>2</sub>SO<sub>4</sub> or with propanolic H<sub>2</sub>SO<sub>4</sub> gave the corresponding Me ether [leaflets, m. 73-4.5° (MeOH)] and Pr ether [oil; citrate, decomposed at 148°], resp.

3-Methyl-3-azabicyclo[3.2.1]octan-8-one (3 g.) in 20 ml. dry tetrahydrofuran (THF) added slowly with stirring to a Grignard solution prepared by refluxing 4.1 g. PhBr, 0.61 g. Mg turnings, and 20 ml. dry Et<sub>2</sub>O, the mixture stirred 3 hrs. at room temperature, and a saturated NH<sub>4</sub>Cl solution added to the cooled mixture gave 2.51 g. 3-methyl-8 $\beta$ -hydroxy-8 $\alpha$ -phenyl-3-azabicyclo[3.2.1]octane (IV), m. 130-1°. A mixture of 500 mg. IV and 5 ml. (EtCO)<sub>2</sub>O heated 3 hrs. at 160-5° gave 533 mg. IVa, b<sub>0.5</sub> 150° (bath temperature). A mixture of 515 mg. I and 5 ml. (EtCO)<sub>2</sub>O heated 4 hrs. at 160-70° gave 49 mg. V, b<sub>1</sub> 130° (bath temperature), isolated as the picrate, yellow leaflets, m. 137-9°, and 335 mg. VI, b<sub>0.05</sub> 180° (bath temperature). A solution of 0.44 g. VI in 10 ml. Et<sub>2</sub>O 4 hrs. with excess MeI gave 0.74 g. V methiodide, leaflets, m. 198-9° (MeOH-Et<sub>2</sub>O). III treated similarly with (EtCO)<sub>2</sub>O also gave V and VI. VI (294 mg.) in 3 ml. cold dry tetrahydrofuran (THF) treated portionwise with 50 mg. LiAlH<sub>4</sub>, and the mixture then refluxed 3 hrs. gave 253 mg. pale yellow liquid, which, on refluxing 2.5 hrs. in 5 ml. Et<sub>2</sub>O with excess MeI gave 399 mg. VII, m. 163-5° (Et<sub>2</sub>O-MeOH). Hofmann degradation of V methiodide gave NMe<sub>3</sub> [isolated as the picrate (70 mg.)] and 0.12 g. VIII, b<sub>20</sub> 160° (bath temperature). VII similarly gave 43 mg. NMe<sub>2</sub>Pr picrate and 93 mg. VIII. A solution of 310 mg. VI in 25 ml. 1:1:1 MeOH-H<sub>2</sub>O-concentrated HCl refluxed 3 hrs. gave 30 mg. IX, m. 102-3° (hexane-EtOAc). LiAlH<sub>4</sub> (30 mg.) added in small portions to a stirred solution of 191 mg. IX in 2 ml. dry THF, and the mixture refluxed 6 hrs. gave 128 mg. X, b<sub>0.05</sub> 150° (bath temperature). X with MeI gave 77% of the methiodide (XI), decomposed at 150° (MeOH-Et<sub>2</sub>O). Hofmann degradation of XI with Ag<sub>2</sub>O gave 120 mg. 5-hexenyl phenyl ketone, b<sub>7</sub> 180-90°

(bath temperature); 2,4-dinitrophenylhydrazone m. 142-3° (EtOH). A solution of 2.5 g. I (or III), 3 g. HOAc, and 18 g. NaOAc in 200 ml. H2O heated at 160-70° in an autoclave 3 hrs. gave 57 mg. of an amine (C12H21N), m. 47.5-8.5° [picrate (C21H24O4N4), decomposed at 190°], and 404 mg. V. These facts illustrate the tendency of the skeleton of 9-phenylazabicyclo[3.3.1]nonane to yield a carbonium ion. The structures are confirmed by ir, uv, and N.M.R. spectra.


IT 15466-28-1P 15466-29-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 15466-28-1 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8-phenyl-, (8-syn)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 15466-29-2 CAPLUS

CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-methyl-8 $\alpha$ -phenyl-, propionate  
(ester) (8CI) (CA INDEX NAME)

Relative stereochemistry.



=> FIL STNGUIDE

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |

FULL ESTIMATED COST

|       |        |
|-------|--------|
| 61.78 | 228.93 |
|-------|--------|

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |

CA SUBSCRIBER PRICE

|       |       |
|-------|-------|
| -9.00 | -9.00 |
|-------|-------|

FILE 'STNGUIDE' ENTERED AT 09:40:08 ON 06 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 1, 2006 (20061201/UP).

=> d his

(FILE 'HOME' ENTERED AT 09:38:45 ON 06 DEC 2006)

FILE 'REGISTRY' ENTERED AT 09:39:01 ON 06 DEC 2006

L1 STRUCTURE UPLOADED

L2 13 S L1  
L3 204 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:39:38 ON 06 DEC 2006  
L4 12 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 09:40:08 ON 06 DEC 2006

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

229.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-9.00

STN INTERNATIONAL LOGOFF AT 09:43:01 ON 06 DEC 2006